drugset
drugset / Trial / NCT03000569

A Study to Evaluate SAGE-217 in Participants With Parkinson's Disease

NCT03000569 ↗

Phase 2 Completed 29 enrolled Biogen
Non-randomizedSequentialOpen-labelTreatment

Summary

This study assesses the safety, tolerability, pharmacokinetics and efficacy of SAGE-217 in 29 participants with moderate to severe Parkinson's Disease.

Timeline

Start
2016-11-30
Primary completion
2017-09-11
Completion
2017-09-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Zuranolone Small molecule 30 mg Oral
Background Levodopa Small molecule — —

Indications

Parkinson disease